PatentJul 23, 2026, 07:33 AM
Autonomix Medical Secures New US Patent for ANS Assessment
AI Summary
Autonomix Medical, Inc. announced the issuance of U.S. Patent No. 12,471,776, titled "ANS Assessment Systems, Kits, and Methods." This patent significantly strengthens the company's intellectual property portfolio for its proprietary autonomic nervous system technologies. The patent broadly covers systems and methods for monitoring physiologic signals to assess ANS activity, including technologies for patient selection, procedural guidance, and post-treatment monitoring across neuromodulation applications. CEO Brad Hauser stated that this innovation reinforces their vision of building a differentiated technology platform for precision nerve-targeted treatments.
Key Highlights
- U.S. Patent No. 12,471,776 issued to Autonomix Medical.
- Patent titled "ANS Assessment Systems, Kits, and Methods."
- Covers systems, devices, and methods for monitoring autonomic nervous system (ANS) activity.
- Includes technologies for evaluating sympathetic and parasympathetic nervous system function.
- Supports patient selection, procedural guidance, treatment feedback, and post-treatment monitoring.
- Strengthens the company's intellectual property portfolio for nerve-targeted treatments.
- Aims to improve precision and effectiveness of future nerve-targeted therapies.
Price Impact
More from AMIX